BR112014022703A2 - método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit - Google Patents

método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit Download PDF

Info

Publication number
BR112014022703A2
BR112014022703A2 BR112014022703-9A BR112014022703A BR112014022703A2 BR 112014022703 A2 BR112014022703 A2 BR 112014022703A2 BR 112014022703 A BR112014022703 A BR 112014022703A BR 112014022703 A2 BR112014022703 A2 BR 112014022703A2
Authority
BR
Brazil
Prior art keywords
substituted
pyrazin
unsubstituted
tor kinase
methyl
Prior art date
Application number
BR112014022703-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Shuichan Xu
Kristen Mae Hege
Heather Raymon
Lilly Loraine Wong
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of BR112014022703A2 publication Critical patent/BR112014022703A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014022703-9A 2012-03-15 2013-03-14 método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit BR112014022703A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US61/611,361 2012-03-15
US201261715323P 2012-10-18 2012-10-18
US61/715,323 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112014022703A2 true BR112014022703A2 (pt) 2021-05-04

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014022703-9A BR112014022703A2 (pt) 2012-03-15 2013-03-14 método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit

Country Status (21)

Country Link
US (1) US20130245026A1 (cg-RX-API-DMAC7.html)
EP (1) EP2825170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015510891A (cg-RX-API-DMAC7.html)
KR (3) KR102122617B1 (cg-RX-API-DMAC7.html)
CN (2) CN104519885A (cg-RX-API-DMAC7.html)
AU (1) AU2013203153B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014022703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2866872A1 (cg-RX-API-DMAC7.html)
EA (1) EA028414B1 (cg-RX-API-DMAC7.html)
ES (1) ES2677874T3 (cg-RX-API-DMAC7.html)
IL (1) IL234602B (cg-RX-API-DMAC7.html)
MX (1) MX360878B (cg-RX-API-DMAC7.html)
MY (1) MY174022A (cg-RX-API-DMAC7.html)
NI (1) NI201400111A (cg-RX-API-DMAC7.html)
NZ (1) NZ628416A (cg-RX-API-DMAC7.html)
PH (1) PH12014502029B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201405707XA (cg-RX-API-DMAC7.html)
TW (1) TWI583385B (cg-RX-API-DMAC7.html)
UA (1) UA114315C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013138557A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406706B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
US20140314673A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы

Also Published As

Publication number Publication date
WO2013138557A1 (en) 2013-09-19
TW201343168A (zh) 2013-11-01
NI201400111A (es) 2015-01-15
AU2013203153B2 (en) 2015-09-03
NZ628416A (en) 2016-04-29
JP2019108368A (ja) 2019-07-04
PH12014502029A1 (en) 2014-11-24
ZA201406706B (en) 2016-05-25
TWI583385B (zh) 2017-05-21
JP2021102637A (ja) 2021-07-15
KR20140138927A (ko) 2014-12-04
EA028414B1 (ru) 2017-11-30
EA201491699A1 (ru) 2015-02-27
CA2866872A1 (en) 2013-09-19
IL234602B (en) 2020-05-31
SG11201405707XA (en) 2014-10-30
HK1201750A1 (en) 2015-09-11
CN104519885A (zh) 2015-04-15
MX2014011077A (es) 2014-10-14
CN108992446A (zh) 2018-12-14
KR20200070416A (ko) 2020-06-17
JP2015510891A (ja) 2015-04-13
MY174022A (en) 2020-03-04
ES2677874T3 (es) 2018-08-07
KR102122617B1 (ko) 2020-06-12
EP2825170B1 (en) 2018-05-09
KR20210071101A (ko) 2021-06-15
EP2825170A1 (en) 2015-01-21
IL234602A0 (en) 2014-11-30
UA114315C2 (uk) 2017-05-25
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
US20130245026A1 (en) 2013-09-19
MX360878B (es) 2018-11-21

Similar Documents

Publication Publication Date Title
JP6470821B2 (ja) Torキナーゼ阻害剤を用いた癌の治療
JP6470822B2 (ja) Torキナーゼ阻害剤を用いた癌の治療
AU2013203153B2 (en) Treatment of cancer with TOR kinase inhibitors
JP6470820B2 (ja) Torキナーゼ阻害剤を用いた癌の治療
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
HK1239543A1 (en) Treatment of cancer with tor kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
AU2015201138A1 (en) Treatment of cancer with TOR kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2627 DE 11-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.